There is no comparative cost-utility study between 131I therapy and antithyroid drugs (ATD) therapy for Graves' disease, though 131I therapy has higher remission rate and less side effects. The objective of the study was to analyze the cost-utility of ATD therapy versus 131I therapy by calculating life-long medical costs and utility, based on the responses of Graves' disease patients to questio...

As we have reported recently, the human neuroblastoma cell line SK-N-SH is able to take up and store m-iodobenzylguanidine (mIBG). This is in contrast to several other neuroblastoma cell lines, among which are SK-N-LO cells. Both cell lines were used in cell killing experiments with unlabeled and radioactive-labeled mIBG. Using 1-200 microCi m-[131I]IBG (1 h incubation time), only SK-N-SH cells...

We have investigated the therapeutic efficacy of a single injection of 131I-labeled murine mouse monoclonal antibody (NP-4) against carcinoembryonic antigen using the human colonic tumor xenograft, GW-39, grown in the cheek pouches of adult hamsters. Therapeutic efficacy was dependent on the dose of radioactivity, the specificity of the antibody for the tumor, and the size of the tumor when the...

HTLV-I carriers or patients with HTLV-I associated myelopathy (HAM) are prone to immune-mediated inflammatory disorders. We present a 44-year-old female with HAM who developed Graves' disease. She developed severe Graves' ophthalmopathy shortly after 131I therapy, concurrently with a remarkable increase in TSH-receptor antibody titer. Ophthalmopathy was aggravated in spite of prednisolone thera...

However, we would like to question whether there may be typographical errors in the article. On page 137, in line 10 of the right column, the amount of 131I is given as 54 μCi. On page 138, in line 18 of the left column, the amount of 131I is given as 49 μCi. Moreover, on page 138, in line 14 of the right column, the amount of 131I is given as 49 μCi. We would like to question whether the unit ...

A wide spectrum of potentially misleading artefacts can arise in 131I whole body scans from various anatomical variants and physiological processes as well as several unrelated non-thyroidal disease processes. A proper understanding of the causes of false positive 131I scans is essential for accurate interpretation of the images and to obviate diagnostic errors which may lead to administration ...

Between 1999 and June 2001, 55 unselected thyrotoxic patients were prescribed 200 MBq radioactive iodine (131I). None of these patients received a thionamide such as carbimazole or propylthiouracil within two weeks of treatment or subsequently. Symptom relief was achieved using beta blockers alone. Remission at one year was achieved in 84% of these patients and of these 62% were hypothyroid and...

A 47-year-old man had surgery for paraaortic paraganglioma in 1980 and 1985. In 1987, his urinary excretion of catecholamines and metabolites was extremely high. Scintigraphy with 131I-metaiodobenzylguanidine (MIBG) showed multiple bone and liver metastases. He was treated twice with infusions of 3.7 GBq of 131I-MIBG. After the first treatment, he had transient hypertension and pain in the back...

The possibility of using 131I-macroaggregated al bumin ( 131I-MAA) intra-arterially in identifying hepatic neoplasms was raised by King, Wood, Morlen and Colapinto in a report of a case of clinical pathologic correlation (1 ) . Blank and Tyson in 1969 injected 131I-MAA through percutaneously placed intra-arterial hepatic catheters in 12 patients, and scans showed positive images of abnormal are...